- CSO Kevin Foley to highlight application of company’s innovative CHAMP® technology to target ERK5, an emerging cancer target
BOSTON, MA and HANGZHOU, China, October 12, 2023 -- Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today announced that Kevin P. Foley, Ph.D., Co-founder and Chief Scientific Officer of Ranok, will present a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA USA, 11-15 October 2023. The poster will describe the identification of tumor-targeted, selective protein degraders of the emerging cancer kinase target ERK5 (MAPK7) using Ranok’s CHAMP® technology platform. This work was done in collaboration with the laboratory of Dr. Elisabetta Rovida of the University of Florence, Florence, Italy.
Details for the poster presentation are as follows:
Title: Tumor-selective, chaperone-mediated targeting of ERK5 (MAPK7)
Date and Time: 14 October 2023 at 12:30-4:00 PM ET
Presenter: Kevin P. Foley, Ph.D., Ranok’s Co-founder and Chief Scientific Officer
Session: Therapeutic Agents – Other
Poster: Will be available online at Ranok Therapeutics' Events & Presentations beginning on Saturday 14 October 2023
A second poster presentation from the laboratory of Ranok’s collaborator, Dr. Takeshi Shimamura of the University of Illinois Chicago, Chicago, Illinois, USA will discuss the application of CHAMP technology to treat resistance to KRAS(G12D) inhibitors in cancer:
Title: Treating KRAS(G12D) inhibitor resistance using a KRAS- and HSP90 chaperone-targeted hetero-bispecific small molecule agent.
Date and Time: 13 October 2023 at 12:30-4:00 PM ET Presenter: Ines Pulido, Ph.D., University of Illinois Chicago Session: Drug resistance and modifiers
About Ranok’s CHAMP® platform
Ranok’s proprietary Chaperone-mediated Protein Degradation/Degrader (CHAMP®) platform and Chaperone-Tether Library™ are based on our founders’ extensive backgrounds researching protein homeostasis. CHAMP technology takes advantage of the cellular chaperone network, which regulates the folding and stability of proteins, distinguishing it from other targeted protein degradation approaches. CHAMP has a number of unique advantages, such as the evasion of mechanisms of drug resistance, and is designed to improved safety and efficacy due to the selective targeting of disease tissues.
Ranok’s most advanced oncology program, RNK05047, is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMP®. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase 1/2 trial of RNK05047 currently underway in the
U.S. that will assess its safety, tolerability and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints. Additional information on this clinical trial (NCT05487170) can be found at www.clinicaltrials.gov.
About Ranok Therapeutics
Ranok is a privately held biopharmaceutical company that is pioneering CHAMP, an innovative approach to targeted protein degradation for the discovery and development of novel therapeutics. Our R&D team brings deep biological insight and chemistry expertise to rapidly identify and advance CHAMP degraders for a variety of important disease targets, with the goal to create transformative medicines that benefit patients around the world suffering from cancer and other serious diseases. For more information, please visit the company website at www.ranoktherapeutics.com or follow us on Twitter (@RanokTx) and LinkedIn.
US Media & Investor Contact:
Ms. Beth Kurth
Conway Communications firstname.lastname@example.org
China Media & Investor Contact:
Dr. Liang Ma
Ranok Therapeutics email@example.com